Because they moved some costs out of the operating expenses and into investing activities. Those expenses are R&D in nature and are expected to be offset every year by the R&D rebate (a good chunk of it). The next 4C should show a receipt of circa $1.5mio from such rebate for FY24. If they operate at a too tight runway, they may need to borrow against future R&D receivables.
Also, the cash position used in these calcs does not consider the "net client book", and should be $4.8mio instead.
If you take the above into consideration, the runway was a lot tighter, circa 2.5 quarters. But they are following the conventions of this report, not doing anything wrong and the R&D rebate receipt will extend it.
This 4C will somehow "reset" the financials: R&D rebate received, consolidation of Limepay acquisition, validation or not of the announced progress with CC. Very difficult to predict. I fear the Limepay acquisition will not be positive to the bottom line. If it was, SPX would not have been able to acquire it. And I just ignore any new revenues announcement until I see them confirmed in 4C.
If we fast forward 8 months, the options expiring in August look under water. At which stage does this impact their financial risk management? Something for the new CFO...
- Forums
- ASX - By Stock
- Ann: Resignation of CFO
SPX
spenda limited
Add to My Watchlist
9.09%
!
0.6¢

Because they moved some costs out of the operating expenses and...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.6¢ |
Change
0.001(9.09%) |
Mkt cap ! $27.69M |
Open | High | Low | Value | Volume |
0.6¢ | 0.7¢ | 0.6¢ | $23.32K | 3.880M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 280696 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 18216262 | 29 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 280696 | 0.006 |
51 | 24939523 | 0.005 |
8 | 15700000 | 0.004 |
9 | 26100000 | 0.003 |
5 | 17000002 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 18124441 | 28 |
0.008 | 4141717 | 24 |
0.009 | 11710538 | 17 |
0.010 | 846836 | 6 |
0.011 | 527004 | 4 |
Last trade - 15.59pm 27/06/2025 (20 minute delay) ? |
Featured News
SPX (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online